Filtros de búsqueda

Lista de obras de

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

artículo científico publicado en 2016

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

artículo científico publicado en 2004

A Feasibility Study Showing [(68)Ga]Citrate PET Detects Prostate Cancer

artículo científico publicado en 2016

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).

artículo científico publicado en 2015

A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer

artículo científico publicado en 2020

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2015

A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy

A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study

artículo científico publicado en 2017

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

artículo científico publicado en 2011

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

artículo científico publicado en 2010

A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies

artículo científico publicado en 2009

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer

artículo científico publicado en 2007

A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma

artículo científico publicado en 2005

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

artículo científico publicado en 2006

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

artículo científico publicado en 2003

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

artículo científico publicado en 2008

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008

artículo científico publicado en 2006

A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer ⬇️

artículo científico publicado el 4 de octubre de 2011

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

artículo científico publicado en 2005

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

scientific article published on 23 January 2009

A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.

artículo científico publicado en 2007

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

artículo científico publicado en 2007

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy

artículo científico publicado en 2006

A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.

artículo científico publicado en 2008

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

artículo científico publicado en 2007

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.

artículo científico publicado en 2000

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

artículo científico publicado en 2006

A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

artículo científico publicado en 2014

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

artículo científico publicado en 2015

Abiraterone in metastatic prostate cancer without previous chemotherapy

artículo científico publicado en 2013

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

artículo científico publicado en 2006

Abstract A12: Identification of pathways associated with abiraterone resistance in metastatic castration resistant prostate cancer: Preliminary results from the SU2C/AACR West Coast Prostate Cancer Dream Team

article

Accelerating precision medicine in metastatic prostate cancer

artículo científico publicado en 2020

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer

artículo científico publicado en 2014

Activities and accomplishments of the cancer and leukemia group B genitourinary committee.

artículo científico publicado en 2006

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

artículo científico publicado en 2007

Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.

artículo científico publicado en 2006

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

artículo científico publicado en 2007

Advances in prostate cancer

scientific article published on 01 May 2004

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer

artículo científico publicado en 2016

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer

artículo científico publicado en 2021

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors

artículo científico publicado en 2017

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

artículo científico publicado en 2015

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)

scientific article published on 03 May 2019

Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study

scientific article published on 01 March 2000

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer

artículo científico publicado en 2017

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

artículo científico publicado en 2003

Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development

artículo científico publicado en 2007

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale

artículo científico publicado en 2006

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

artículo científico publicado en 2008

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

artículo científico publicado en 2004

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival

scientific article published on 01 June 2018

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

artículo científico publicado en 2005

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

artículo científico publicado en 2018

Apalutamide and Metastasis-free Survival in Prostate Cancer

artículo científico publicado en 2018

Apalutamide and Overall Survival in Prostate Cancer

scientific article published on 06 September 2020

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

scientific article published on 01 November 2019

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

artículo científico publicado en 2009

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial

artículo científico publicado en 2019

Autoantibody landscape in patients with advanced prostate cancer

scientific article published on 23 September 2020

Bevacizumab and everolimus in renal cancer: a rational way forward

artículo científico publicado en 2010

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).

artículo científico publicado en 2014

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

artículo científico publicado en 2008

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

artículo científico publicado en 2004

Bladder cancer

artículo científico publicado en 2009

Bladder cancer

artículo científico publicado en 2013

Bladder cancer. Clinical guidelines in oncology

artículo científico publicado en 2006

Bladder cancer. Clinical practice guidelines in oncology

artículo científico publicado en 2005

Bloodborne biomolecular markers in prostate cancer development and progression

artículo científico publicado en 2002

CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield

artículo científico publicado en 2017

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

artículo científico publicado en 2008

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

artículo científico publicado en 2016

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

scientific article published on 09 August 2019

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial ⬇️

artículo científico publicado el 19 de noviembre de 2012

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

artículo científico publicado en 2018

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

artículo científico publicado en 2003

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

scientific article published on 24 July 2020

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

artículo científico publicado en 2004

Cancer and Leukemia Group B trials for advanced prostate cancer.

artículo científico publicado en 1996

Castrate-resistant prostate cancer: therapeutic strategies

artículo científico publicado en 2010

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

artículo científico publicado en 2010

Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

artículo científico publicado en 2017

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer

artículo científico publicado en 2019

Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer

artículo científico publicado en 2020

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy

artículo científico publicado en 2017

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

artículo científico publicado en 2018

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

scientific article published on 20 December 2018

Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer

artículo científico publicado en 2020

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor

artículo científico publicado en 2006

Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies

artículo científico publicado en 2006

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

artículo científico publicado en 2006

Clinical trials in patients with biochemically relapsed prostate cancer

artículo científico publicado en 2006

Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate‐risk prostate cancer ⬇️

artículo científico publicado el 25 de julio de 2011

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809

artículo científico publicado en 2008

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

artículo científico publicado en 2006

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

artículo científico publicado en 2003

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel

artículo científico publicado en 2020

Complementary and alternative therapies in prostate cancer.

artículo científico publicado en 2002

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

artículo científico publicado en 2017

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2020

Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

scientific article published on 27 September 2018

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer

article

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer

artículo científico publicado en 2022

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

artículo científico publicado en 2009

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

artículo científico publicado en 2008

Developing Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer

artículo científico publicado en 2010

Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients ⬇️

artículo científico publicado el 5 de septiembre de 2012

Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer ⬇️

artículo científico publicado el 1 de agosto de 2001

Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?

artículo científico publicado en 2020

Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer

artículo científico publicado en 2020

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer

artículo científico publicado en 1996

Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate

artículo científico publicado en 2005

Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial

scientific article published on 01 January 2020

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

article

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: Results of a phase II study ⬇️

artículo científico publicado el 2 de octubre de 2010

Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer

scientific article published on 19 June 2020

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782

artículo científico publicado en 2011

Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer

artículo científico publicado en 2005

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

artículo científico publicado en 2004

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

artículo científico publicado en 1999

Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications

artículo científico publicado en 2017

Emerging biological observations in prostate cancer

artículo científico publicado en 2010

Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

scholarly article published in Investigational New Drugs

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer

artículo científico publicado en 2007

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

artículo científico publicado en 2006

Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer

scientific article published on 01 March 2007

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer

scientific article published on 28 March 2019

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Germline and Somatic Mutations in Prostate Cancer for the Clinician

scientific article published on 01 May 2019

Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer

scientific article published on 19 November 2019

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

artículo científico publicado en 2007

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer

scientific article published on 15 May 2018

High risk biochemical relapse and the timing of androgen deprivation therapy

artículo científico publicado en 2006

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer

artículo científico publicado en 2017

High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer

artículo científico publicado en 2005

Hormone-refractory Prostate Cancer

artículo científico publicado en 2002

Hormone-refractory prostate cancer: an evolving standard of care.

artículo científico publicado en 1999

How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials

artículo científico publicado en 2019

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

artículo científico publicado en 2015

Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study

scientific article published on 04 November 2019

Immunotherapeutics in development for prostate cancer

artículo científico publicado en 2009

Immunotherapy for prostate cancer

artículo científico publicado en 2003

Immunotherapy for prostate cancer

artículo científico publicado en 2007

Immunotherapy for prostate cancer

artículo científico publicado en 2006

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

artículo científico publicado en 2007

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells

artículo científico publicado en 2006

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

artículo científico publicado en 2000

Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer

artículo científico publicado en 2017

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

artículo científico publicado en 2015

Impact of race on survival in men with metastatic hormone-refractory prostate cancer.

artículo científico publicado en 2004

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

artículo científico publicado en 2012

In Reply

In Reply

article published in 2008

Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT

scientific article published on 01 May 2019

Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate

artículo científico publicado en 2014

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

artículo científico publicado en 2009

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel

artículo científico publicado en 2014

Intermittent chemotherapy for metastatic hormone refractory prostate cancer

artículo científico publicado en 2006

Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases

artículo científico publicado en 2019

Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.

artículo científico publicado en 2007

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study

artículo científico publicado en 2018

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium

artículo científico publicado en 2010

Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients

artículo científico publicado en 2015

Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer

artículo científico publicado en 2005

Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer

artículo científico publicado en 2002

Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer

artículo científico publicado en 2002

Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.

artículo científico publicado en 2017

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

scientific article published on 25 February 2019

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

artículo científico publicado en 2020

Management of hormone refractory prostate cancer

artículo científico publicado en 2007

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

artículo científico publicado en 2016

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

artículo científico publicado en 2015

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

artículo científico publicado en 2018

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

artículo científico publicado en 2006

Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.

artículo científico publicado en 2017

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

artículo científico publicado en 2016

Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate

artículo científico publicado en 2013

Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making

scientific article published on 28 June 2017

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

artículo científico publicado en 2005

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811

artículo científico publicado en 2008

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

artículo científico publicado en 2005

Neoadjuvant strategies for prostate cancer prior to radical prostatectomy

artículo científico publicado en 2002

Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes

artículo científico

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

artículo científico publicado en 2002

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types

scientific article published on 22 April 2019

Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer

artículo científico publicado en 2017

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer

artículo científico

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer

artículo científico publicado en 2002

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel

artículo científico publicado en 2018

Overview of bladder cancer trials in the Cancer and Leukemia Group B.

artículo científico publicado en 2003

PC-SPES and prostate cancer

scientific article published on 01 February 2002

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

artículo científico publicado en 2001

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

artículo científico publicado en 2008

Penile cancer: Clinical Practice Guidelines in Oncology

artículo científico publicado en 2013

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

artículo científico publicado en 2016

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

artículo científico publicado en 2008

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

artículo científico publicado en 2018

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

artículo científico publicado en 2010

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

scientific article published on 26 April 2007

Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consort

artículo científico publicado en 2009

Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response ⬇️

artículo científico publicado el 15 de julio de 2011

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

artículo científico publicado en 2008

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

artículo científico publicado en 2001

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome

artículo científico publicado en 2007

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study

artículo científico publicado en 2005

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

artículo científico publicado en 2010

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

artículo científico publicado en 2006

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

artículo científico publicado en 2009

Practice and progress in kidney cancer: methodology for novel drug development

artículo científico publicado en 2004

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer

artículo científico publicado en 2017

Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study

artículo científico publicado en 2005

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab

artículo científico publicado en 2015

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies

artículo científico publicado en 2015

Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer

artículo científico publicado en 2005

Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480

scientific article published on 01 March 2006

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

artículo científico publicado en 2003

Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy

artículo científico publicado en 2013

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy

artículo científico publicado en 2013

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy

artículo científico publicado en 2005

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

artículo científico publicado en 2005

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

artículo científico publicado en 2001

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer

artículo científico publicado en 2001

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.

artículo científico publicado en 2003

Progress in detection and treatment of prostate cancer

artículo científico publicado en 2005

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

scientific article published on 20 April 2009

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

artículo científico publicado en 2013

Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?

artículo científico publicado en 2015

Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer

artículo científico publicado en 2000

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

artículo científico publicado en 2004

Prospects for the use of ipilimumab in treating advanced prostate cancer

artículo científico

Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions

artículo científico publicado en 2015

Prostate Cancer, Version 1.2016.

artículo científico publicado en 2016

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2019

Prostate cancer immunology: biology, therapeutics, and challenges

artículo científico publicado en 2005

Prostate cancer update

artículo científico publicado en 2002

Prostate cancer update

scientific article published on 01 May 2003

Prostate cancer update: 2005.

artículo científico publicado en 2006

Prostate cancer update: 2006.

artículo científico publicado en 2007

Prostate cancer update: 2007.

artículo científico publicado en 2008

Prostate cancer, version 1.2014.

artículo científico publicado en 2013

Prostate cancer, version 2.2014

artículo científico publicado en 2014

Prostate cancer: evolution or revolution?

artículo científico publicado en 2011

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

scientific article published on 11 September 2019

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

artículo científico publicado en 2013

Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response

artículo científico publicado en 2002

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

artículo científico publicado en 2003

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

artículo científico publicado en 2009

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.

artículo científico publicado en 2004

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results

artículo científico publicado en 2015

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

artículo científico publicado en 2014

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

artículo científico publicado en 2002

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

artículo científico publicado en 2012

Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

artículo científico publicado en 2012

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer

artículo científico publicado en 2017

Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.

artículo científico publicado en 2006

Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer

scientific article published on 06 November 2019

Reply to A. Dalla Volta et al

artículo científico publicado en 2018

Reply to F. Valcamonico et al.

artículo científico publicado en 2014

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

artículo científico publicado en 2014

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

artículo científico publicado en 2006

Role of secondary hormonal therapy in the management of recurrent prostate cancer

artículo científico publicado en 2003

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

artículo científico publicado en 2004

Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer

artículo científico publicado en 2004

Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

artículo científico publicado en 2004

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

artículo científico publicado en 1997

Secondary hormonal manipulation of prostate cancer

artículo científico publicado en 2002

Secondary hormonal manipulations in prostate cancer

artículo científico publicado en 2005

Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens

artículo científico publicado en 2014

Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial ⬇️

artículo científico publicado el 1 de agosto de 2013

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival

artículo científico publicado en 2001

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

artículo científico publicado en 2010

Sipuleucel-T

scientific article published on 01 July 2010

Sipuleucel-T for the treatment of prostate cancer

artículo científico publicado en 2008

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

artículo científico publicado en 2010

Small-cell/neuroendocrine prostate cancer: a growing threat?

artículo científico publicado en 2014

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

artículo científico publicado en 2000

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

artículo científico publicado en 2016

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

artículo científico publicado en 2005

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

artículo científico publicado en 2000

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

scientific article published on 28 February 2020

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer

artículo científico publicado en 2016

Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

artículo científico

Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team

artículo científico publicado en 2016

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer

artículo científico publicado en 2018

Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study

artículo científico publicado en 2006

The DNA methylation landscape of advanced prostate cancer

scientific article published on 13 July 2020

The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance

artículo científico publicado en 2019

The case for secondary hormonal therapies in the chemotherapy age.

artículo científico publicado en 2006

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90

artículo científico publicado en 2013

The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials

artículo científico publicado en 2007

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer

artículo científico publicado en 2021

The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels

artículo científico publicado en 2009

The potential for prostate cancer immunotherapy

artículo científico publicado en 2003

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

artículo científico publicado en 2005

The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer

artículo científico publicado el 1 de julio de 2011

The selection of hormonal therapy in prostate cancer: who, when, and for how long?

artículo científico publicado en 2004

Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma

artículo científico publicado en 2004

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

artículo científico publicado en 2014

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

scientific article published on 18 May 2020

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer

artículo científico publicado en 2017

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy

artículo científico publicado en 2008

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

artículo científico publicado en 2016

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study

artículo científico publicado en 2007

Update on chemotherapy for advanced bladder cancer

artículo científico publicado en 2005

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

artículo científico publicado en 2014

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

scientific article published on 21 January 2014

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study

artículo científico publicado en 2001

Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity

artículo científico publicado en 2019

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

artículo científico publicado en 2008

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda